Modern Chemotherapy Management of Recurrent Ovarian Cancer: A Multicentre Study

Clinical Oncology

Volumn 19, Issue 2, 2007, Pages 129-134

  Chan, S ^a   Griffin, M ^a   Stewart, J ^b   Gregory, K ^c,d   Hughes, A ^e   Awwad, S ^f   Allerton, R ^g   Pledge, S ^h   Thomas, H ⁱ   Percival, F ^j   on behalf of the Ovarian Cancer Audit Group UK, ^k  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b NORTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^c ROYAL SOUTH HANTS HOSPITAL   (United Kingdom)

^d SALISBURY DISTRICT HOSPITAL   (United Kingdom)

^e QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^f PRINCESS ROYAL HOSPITAL   (United Kingdom)

^g NEW CROSS HOSPITAL   (United Kingdom)

^h WESTON PARK HOSPITAL   (United Kingdom)

ⁱ Royal Surrey County Hospital NHS Trust   (United Kingdom)

^j PH ASSOCIATES   (United Kingdom)

^k NONE

more..

Author keywords

Audit; chemotherapy; disease relapse; drug treatment; gynaecological malignancy; ovarian cancer

Indexed keywords

ALTRETAMINE; CARBOPLATIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; NEW DRUG; PACLITAXEL; PLATINUM DERIVATIVE; TAMOXIFEN; TOPOTECAN; TREOSULFAN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RELAPSE; CASE MANAGEMENT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG USE; ERYTHEMA; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL AUDIT; NATIONAL HEALTH SERVICE; OVARY CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT CANCER; RETROSPECTIVE STUDY; SURVIVAL TIME; TREATMENT OUTCOME; UNITED KINGDOM;

ADULT; AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; CYSTADENOCARCINOMA, SEROUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 33846613340     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2006.10.002     Document Type: Article

References (14)

1. Cancer Research UK. Cancer incidence statistics. (. http://www.cancerreserachuk.org/aboutcancer/statistics/incidence )
2. National Institute of Clinical Excellence. Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer, a review of Technology Appraisal Guidance 28, 45 and 55. Technology Appraisal 91: 25 May 2005.
3. Kirwan J.M.J., Tincello D.G., and Herod J.J.O. Effect of delays in primary care referral on survival of women with epithelial ovarian cancer: retrospective audit. Br Med J 324 (2002) 148-151
4. National Institute of Clinical Excellence. Ovarian cancer - taxanes. Technology Appraisal 3: May 2000.
5. National Institute of Clinical Excellence. Guidance on the use of topotecan for the treatment of advanced ovarian cancer. Technology Appraisal 28: August 2001.
6. National Institute of Clinical Excellence. Ovarian cancer (advanced) - pegylated liposomal doxorubicin hydrochloride. Technology Appraisal 45: July 2002.
7. National Institute of Clinical Excellence. Guidance on the use of paclitaxel in the treatment of ovarian cancer. Technology Appraisal 55: January 2003.
8. Merck Pharmaceuticals. Hycamtin SPC. (. http://emc.medicines.org.uk/ ). Last updated 29 September 2004 (accessed 13 October 2005)
9. Redman J.R., Petroni G.R., Saigo P.E., et al. Prognostic factors in advanced ovarian carcinoma. J Clin Oncol 4 (1986) 515-523
10. Hoskins W.J., McGuire W.P., Brady M.F., et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 170 (1994) 974-980
11. Vergote I., De Wever I., Tjalma W., et al. Neo-adjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 286 patients. Gynecol Oncol 71 (1998) 431-436
12. http://www.eortc.be/protoc/Details.asp?Protocol=55971 (accessed 17 July 2006)
13. http://www.ctu.mrc.ac.uk/studies/CHORUS.asp (accessed 17 July 2006)
14. Department of Health. The NHS Cancer Plan. (http://www.dh.gov.uk/assetRoot/04/01/45/13/04014513.pdf (September 2000) )